[1] | Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 2011; 57(11):e101-e198. |
[2] | Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285(18):2370-2375. |
[3] | Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(6 Suppl):546S-592S. |
[4] | Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995; 98(5):476-484. |
[5] | Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22(8):983-988. |
[6] | Thrall G, Lane D, Carroll D, Lip GY. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med 2006; 119(5):448-19. |
[7] | Savelieva I, Camm AJ. Clinical trends in atrial fibrillation at the turn of the millenium. J Intern Med 2001; 250(5):369-372. |
[8] | Savelieva I, Camm J. Update on atrial fibrillation: part I. Clin Cardiol 2008; 31(2):55-62. |
[9] | Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995; 155(5):469-473. |
[10] | Heeringa J, van der Kuip DA, Hofman A, Kors JA, van HG, Stricker BH et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006; 27(8):949-953. |
[11] | Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146(12): 857-867. |
[12] | The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med 1990; 323(22):1505-1511. |
[13] | Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991; 84(2):527-539. |
[14] | Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993; 342(8882):1255-1262. |
[15] | Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991; 18(2):349-355. |
[16] | Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992; 327(20): 1406-1412. |
[17] | Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989; 1(8631):175-179. |
[18] | Fendrick AM. A pharmacoeconomic perspective on stroke prevention in atrial fibrillation. Am J Manag Care 2010; 16(10 Suppl): S284-S290. |
[19] | Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15(5): 625-651. |
[20] | Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361(12):1139-1151. |
[21] | Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365(11):981-992. |
[22] | Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365(10):883-891. |
[23] | Kasmeridis C, Apostolakis S, Ehlers L, Rasmussen LH, Boriani G, Lip GY. Cost effectiveness of treatments for stroke prevention in atrial fibrillation: focus on the novel oral anticoagulants. Pharmacoeconomics 2013; 31(11):971-980. |
[24] | Coyne KS, Paramore C, Grandy S, Mercader M, Reynolds M, Zimetbaum P. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health 2006; 9(5):348-356. |
[25] | Stewart S, Murphy NF, Walker A, McGuire A, McMurray JJ. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004; 90(3):286-292. |
[26] | Wodchis WP, Bhatia RS, Leblanc K, Meshkat N, Morra D. A review of the cost of atrial fibrillation. Value Health 2012; 15(2):240-248. |
[27] | Wu EQ, Birnbaum HG, Mareva M, Tuttle E, Castor AR, Jackman W et al. Economic burden and co-morbidities of atrial fibrillation in a privately insured population. Curr Med Res Opin 2005; 21(10):1693-1699. |
[28] | Hidalgo-Vega A, Askari E, Vidal R, Aranda-Reneo I, Gonzalez-Dominguez A, Ivanova A et al. Direct vitamin k antagonist anticoagulant treatment health care costs in patients with non-valvular atrial fibrillation. BMC Health Serv Res 2014; 14:46. |
[29] | Hersi AS, Alsheikh-Ali AA, Zubaid M, Al SJ. Prospective observational studies of the management and outcomes in patients with atrial fibrillation: A systematic review. J Saudi Heart Assoc 2012; 24(4):243-252. |
[30] | Zubaid M, Rashed WA, Alsheikh-Ali AA, Al-Zakwani I, Almahmeed W, Shehab A et al. Management and 1-year outcomes of patients with atrial fibrillation in the Middle East: Gulf Survey of Atrial Fibrillation Events. Angiology 2014; In Press. |
[31] | Zubaid M, Rashed WA, Alsheikh-Ali AA, Almahmeed W, Shehab A, Sulaiman K et al. Gulf Survey of Atrial Fibrillation Events (Gulf SAFE): design and baseline characteristics of patients with atrial fibrillation in the Arab Middle East. Circ Cardiovasc Qual Outcomes 2011; 4(4):477-482. |
[32] | Zubaid M, Saad H, Ridha M, Mohanan Nair KK, Rashed W, Alhamdan R et al. Quality of anticoagulation with warfarin across Kuwait. Hellenic J Cardiol 2013; 54(2):102-106. |
[33] | Diehr P, Yanez D, Ash A, Hornbrook M, Lin DY. Methods for analyzing health care utilization and costs. Ann Rev Pub Health 1999; 20: 125-144. |
[34] | Johnston KM, Levy AR, Lorigan P, Maio M, Middleton M, Testori A, et al. Economic impact of health care resource utilization patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study). Eur J Can 2012; 48(14):2175-82. |
[35] | Kannel WB, Benjamin EJ. Status of the epidemiology of atrial fibrillation. Med Clin North Am 2008; 92(1):17-40, ix. |
[36] | Olesen JB, Torp-Pedersen C, Hansen ML, Lip GY. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score –1: a nationwide cohort study. Thromb Haemost 2012; 107(6): 1172-1179. |